StockData
Edwards Lifesciences Corp logo

Edwards Lifesciences Corp (EW) stock

EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3060% above fair value
$105.43−1.68 (-1.57%)

Close on Nov 17, 2026Market cap $60.77BP/E 60.6Yield –

Edwards Lifesciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Edwards Lifesciences's operating income for the twelve months ending Jun 30, 2026 was $1.45B, down 1.4% year over year. For fiscal 2025 it was $1.26B, down 8.3% from the year before. The highest annual figure on record is $1.69B in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.26B-8.3%
FY2024Dec 31, 2024$1.38B+5.3%
FY2023Dec 31, 2023$1.31B-12.6%
FY2022Dec 31, 2022$1.50B-11.4%
FY2021Dec 31, 2021$1.69B+88.3%
FY2020Dec 31, 2020$897.60M-21.7%
FY2019Dec 31, 2019$1.15B+53.3%
FY2018Dec 31, 2018$748.20M-31.3%
FY2017Dec 31, 2017$1.09B+45.0%
FY2016Dec 31, 2016$751.20M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$513.20M+24.8%
Q1 FY2026Mar 31, 2026$477.60M+21.0%
Q4 FY2025Dec 31, 2025$151.10M-51.7%
Q3 FY2025Sep 30, 2025$307.10M-12.4%
Q2 FY2025Jun 30, 2025$411.20M+12.2%
Q1 FY2025Mar 31, 2025$394.80M+13.1%
Q4 FY2024Dec 31, 2024$312.60M-9.9%
Q3 FY2024Sep 30, 2024$350.60M-4.2%
Q2 FY2024Jun 30, 2024$366.50M+39.1%
Q1 FY2024Mar 31, 2024$349.00M-10.1%
Q4 FY2023Dec 31, 2023$346.80M+75.4%
Q3 FY2023Sep 30, 2023$365.90M-9.1%
Q2 FY2023Jun 30, 2023$263.50M-42.7%
Q1 FY2023Mar 31, 2023$388.40M-11.5%
Q4 FY2022Dec 31, 2022$197.70M-47.2%
Q3 FY2022Sep 30, 2022$402.40M+3.1%
Q2 FY2022Jun 30, 2022$459.50M-15.2%
Q1 FY2022Mar 31, 2022$438.80M+14.4%
Q4 FY2021Dec 31, 2021$374.40M+6.5%
Q3 FY2021Sep 30, 2021$390.30M+9.1%
Q2 FY2021Jun 30, 2021$542.10M–
Q1 FY2021Mar 31, 2021$383.50M+7.1%
Q4 FY2020Dec 31, 2020$351.40M+13.1%
Q3 FY2020Sep 30, 2020$357.80M+21.6%
Q2 FY2020Jun 30, 2020-$169.70M-163.4%
Q1 FY2020Mar 31, 2020$358.10M+30.6%
Q4 FY2019Dec 31, 2019$310.80M–
Q3 FY2019Sep 30, 2019$294.30M+18.2%
Q2 FY2019Jun 30, 2019$267.50M+6.1%
Q1 FY2019Mar 31, 2019$274.20M+8.6%
Q4 FY2018Dec 31, 2018-$5.30M-101.6%
Q3 FY2018Sep 30, 2018$248.90M+16.3%
Q2 FY2018Jun 30, 2018$252.10M+4.6%
Q1 FY2018Mar 31, 2018$252.50M-15.4%
Q4 FY2017Dec 31, 2017$336.10M–
Q3 FY2017Sep 30, 2017$214.00M–
Q2 FY2017Jun 30, 2017$241.00M–
Q1 FY2017Mar 31, 2017$298.30M–

More Edwards Lifesciences figures

See a number that looks wrong?